Elizabeth Warren’s Bill Protects Corporate Medicine From Its Competition

Senator Elizabeth Warren says the Stop Corporate Takeovers of Physicians Act of 2026 will protect patients from having their medical care controlled by Wall Street.

The bill’s stated objective sounds unobjectionable. Medical decisions should be made by physicians, not investors, insurance executives, or corporate administrators.

But Warren’s proposal does not eliminate corporate influence from medicine. It threatens one of the few competitive forces capable of challenging the corporations that have dominated American healthcare for decades.

The legislation targets private investment and management structures used by growing physician practices while leaving much of the established healthcare system undisturbed.

Its practical effect could be to protect the incumbent corporate world of medicine, particularly the insurance-driven and pharmaceutical-dependent system, from a rapidly growing cash-pay market that is competing for the same patients.

This is not a battle between physicians and corporations.

It is a battle over which healthcare business models will be allowed to compete.

What the Bill Would Do

The Stop Corporate Takeovers of Physicians Act was introduced by Senators Elizabeth Warren, Ron Wyden, and Jeff Merkley, with companion legislation supported in the House by Representatives Val Hoyle, Suhas Subramanyam, and Alexandria Ocasio-Cortez.

The legislation would create a federal corporate-practice-of-medicine framework. It would generally prohibit an entity that is not majority-owned and controlled by licensed healthcare professionals from owning or controlling a medical practice, employing clinicians, contracting for professional medical services, or engaging in the practice of medicine.

It would also impose extensive restrictions on management services organizations, commonly called MSOs.

MSOs provide the nonclinical infrastructure that allows many physician practices to operate and expand. Their services can include payroll, human resources, technology, billing, collections, marketing, scheduling, equipment, real estate, accounting, compliance support, and business administration.

Private investment transactions frequently use an MSO structure because investors are not permitted to own the clinical practice in states with strong corporate-practice-of-medicine restrictions. The physician continues to own the professional entity and control medicine, while the MSO supplies capital and manages nonclinical operations.

Warren’s bill treats many of these arrangements as mechanisms through which investors use “friendly” or “captive” physicians to evade ownership restrictions.

The bill would prohibit an MSO from exercising ultimate authority over matters including:

• Hiring and terminating practice employees

• Provider schedules and compensation

• Staffing levels

• Revenue targets and provider incentives

• The disbursement of practice revenue

• Billing policies

• Prices charged for medical services

• Contracts with third parties

• The transfer of practice interests or assets

• Clinical standards and policies

• Practice branding and advertising

  
  

Management agreements would have to be independently negotiated at arm’s length, and the compensation paid to the MSO would have to reflect fair market value under standards determined by the Federal Trade Commission.

The bill would also broadly prohibit noncompete, nondisclosure, and nondisparagement provisions. Physician owners would have to be licensed and present in a state where the practice treats patients and substantially engaged in delivering medical care.

Violations could result in FTC enforcement, state attorney-general actions, private lawsuits, treble damages, attorney’s fees, disgorgement of revenue, and forced divestiture. The principal provisions would take effect one year after enactment.

This is not simply a bill prohibiting investors from telling physicians what medication to prescribe. It reaches deeply into the financial and operational structure of medical practices.

The Corporate Medicine Warren’s Bill Leaves Standing

Warren presents the legislation as an attack on corporate medicine. But the bill expressly exempts nonprofit and public healthcare providers, hospitals, hospital-affiliated clinics, critical-access hospitals, and rural emergency hospitals from its principal ownership prohibition.

Those exemptions expose the central contradiction in the legislation.

A physician employed by a massive hospital system can still face productivity quotas, limited appointment times, administrative protocols, staffing constraints, billing policies, and institutional pressure. The fact that an organization is legally classified as a nonprofit does not mean it lacks executives, revenue targets, market power, or economic incentives.

Similarly, insurance carriers exert enormous influence over the care patients ultimately receive. They determine network participation, reimbursement rates, prior-authorization requirements, coverage policies, formularies, and whether particular treatments will be paid for at all.

The bill includes insurance companies within its general ownership restrictions, but it does not meaningfully reform the insurance mechanisms that influence medicine every day. It does not eliminate prior authorization. It does not prevent coverage denials. It does not change reimbursement policies. It does not stop insurers from determining which treatments they will finance.

The pharmaceutical industry also exercises enormous influence through drug development, pricing, marketing, formularies, rebates, research funding, and relationships throughout the healthcare system. Warren’s bill does not directly address that influence either.

Instead, the legislation concentrates much of its force on MSOs and investment structures used by independent practices.

The result is a bill that attacks emerging corporate competition while leaving much of the established corporate healthcare infrastructure in place.

The Incumbent Healthcare System Is Facing New Competition

For decades, insurers, hospital systems, and pharmaceutical manufacturers have occupied dominant positions within American healthcare.

Patients have generally entered the system through an insurance network. Physicians have been paid according to reimbursement schedules established by government programs and private insurers. Treatment options have been influenced by coverage policies, formularies, institutional protocols, and the economics of third-party reimbursement.

This system has not consistently rewarded prevention, time with patients, or long-term health optimization.

It frequently pays after the patient becomes sick. It rewards billable procedures, prescriptions, testing, and the management of established disease more reliably than extensive counseling, lifestyle intervention, early risk reduction, or ongoing health optimization.

That does not mean conventional medicine or prescription drugs provide no preventive value. Vaccines, screening programs, blood-pressure medications, lipid management, and many other interventions have prevented disease and saved lives.

But the overall economic structure remains heavily oriented toward treating diagnosable conditions after they develop. Patients increasingly recognize the limitations of that model.

This dissatisfaction has helped produce a growing market for concierge medicine, direct primary care, hormone optimization, metabolic health, weight management, functional medicine, longevity services, and other cash-pay models.

These practices are competing for patients who want more time with their physicians, more extensive testing, greater access, earlier intervention, transparent pricing, and a treatment plan designed around their individual goals rather than the limitations of an insurance reimbursement code.

That competition threatens the established order.

Every patient who moves outside the traditional system for a meaningful portion of his or her care represents a patient making an independent purchasing decision. That patient is no longer relying exclusively on an insurer to determine which physician is affordable, which treatment is covered, or how much time the physician can spend addressing the underlying problem.

Cash-pay medicine gives patients an alternative.

Warren’s bill risks making that alternative harder to build.

The Capital Problem Warren Ignores

An individual physician may have the clinical ability to create an exceptional model of care but lack the capital and operational expertise necessary to bring that model to thousands of patients.

Opening multiple locations requires money. So do diagnostic equipment, compliant technology, sophisticated medical records, trained employees, patient education, quality controls, legal compliance, advertising, cybersecurity, and multistate infrastructure.

Insurance companies, pharmaceutical manufacturers, and hospital systems already possess enormous financial and administrative resources. The independent physician generally does not.

Private capital can close that gap.

An investor can provide the resources required to turn a physician’s clinical model into a scalable organization. An MSO can build and operate the nonclinical infrastructure while the physician remains responsible for diagnosis, prescribing, treatment, clinical protocols, supervision, and patient safety.

Without outside capital, many independent physicians will never be able to compete with established healthcare conglomerates.

Warren’s answer is to restrict the capital and management structures available to those physicians while leaving many entrenched institutions protected by statutory exemptions.

That does not level the playing field. It can reinforce the existing imbalance.

Cash-Pay Practices Face Real Market Accountability

Traditional insurance-based medicine and private cash-pay medicine operate under different forms of accountability.

Patients often select an insurance-based physician because the physician is included in their network. Leaving that physician may mean paying substantially more, traveling farther, or navigating another limited list of approved providers.

The practice receives payment through a third-party reimbursement system. The person receiving the care, the person delivering the care, and the organization paying for the care are different parties with different incentives.

Cash-pay medicine shortens that chain.

The patient chooses the practice and pays the practice directly. The practice must then continually demonstrate that its services justify the price.

A cash-pay practice cannot depend on insurance-network status to produce patients. If it provides poor service, ignores patient concerns, or fails to produce value, patients can stop paying and leave.

This creates a powerful form of market discipline.

It does not guarantee ethical conduct, and it does not eliminate the need for professional regulation. But it means that investors in a cash-pay platform cannot disregard the physician-patient relationship without damaging the very business in which they invested.

The physician’s judgment, credibility, and ability to produce appropriate patient outcomes are central assets of the enterprise.

If investors undermine those assets, they undermine their own investment.

Private Investment and Clinical Independence Can Coexist

Warren’s argument assumes that private investment and independent medical judgment are inherently in conflict.

They are not.

A private investor should never diagnose a patient, select a medication, determine medical necessity, override a prescription, or compel a physician to provide inappropriate treatment.

The physician should retain exclusive control over:

• Diagnosis

• Treatment

• Prescribing

• Clinical protocols

• Medical necessity

• Provider supervision

• Medical records

• Standards of care

• Patient safety

• 
  

But preserving that clinical authority does not require excluding nonphysicians from legitimate business functions.

Professional managers and investors can appropriately support:

• Capital formation

• Facilities and equipment

• Technology

• Marketing

• Human resources administration

• Accounting

• Nonclinical staffing

• Business operations

• Strategic expansion

  
  

Medicine is a profession, but a medical practice is also a business. Pretending otherwise does not protect physicians or patients. It merely leaves physicians less prepared to compete against organizations that already possess vast business resources.

The appropriate legal line is between business support and clinical interference, not between physician practices that accept outside investment and institutions that have already accumulated corporate power.

This Bill Could Strengthen the Very Interests It Claims to Oppose

If private investment in physician-led practices becomes too restricted, expensive, or legally dangerous, the need for capital will not disappear.

Some physicians will remain small and unable to expand. Others will close. Some will sell to hospital systems or accept employment within larger institutions. Innovative practices may never open additional locations or enter underserved markets.

Meanwhile, established insurers, hospital systems, and pharmaceutical companies will continue operating with enormous financial resources, established lobbying operations, institutional relationships, and existing market power.

These industries do not need Warren’s bill to win new patients. They need their emerging competitors to be denied the resources necessary to scale.

Whether or not that is the bill’s intended purpose, it may be its practical effect.

The legislation could protect incumbent corporate medicine by weakening the physician-led businesses trying to compete against it.

Regulation Should Protect Patients Without Protecting Incumbents

There is a legitimate role for regulation.

Nominal physician ownership should not be used to conceal complete investor control. Management fees should reflect real services and fair market value. Physicians should not be punished for refusing to provide medically inappropriate treatment. Investors and MSOs should not interfere with diagnosis, prescribing, medical necessity, or standards of care.

Actual misconduct should be investigated and punished.

But Congress should not use patient protection as a justification for disabling an entire investment model.

A better approach would establish clear national protections for clinical independence while preserving access to legitimate capital and management services. It would also examine corporate influence consistently across private equity firms, insurance companies, hospital systems, pharmaceutical manufacturers, and nonprofit healthcare conglomerates.

If the concern is outside interference with medicine, every source of interference should be subject to scrutiny.

The Wrong Prescription

The Stop Corporate Takeovers of Physicians Act is presented as a bill that will remove corporate interests from the examination room.

In reality, it may protect the corporate interests that are already there.

The traditional healthcare establishment has benefited from an insurance-controlled system in which patients have limited pricing transparency, physicians face reimbursement restrictions, and many treatments become economically available only after they fit within an approved diagnosis or billing code.

Cash-pay medicine is challenging that structure.

It allows patients to purchase care directly from physicians. It creates room for longer consultations, earlier intervention, transparent pricing, individualized treatment, and services that insurers may refuse to cover. It forces practices to compete for the patient’s trust rather than relying on network participation.

Private capital is helping physicians expand that alternative.

The answer is not to give investors control over medicine. The answer is to preserve the physician’s absolute authority over clinical care while allowing responsible investors to finance the infrastructure needed to deliver that care at scale.

Elizabeth Warren says she wants to protect patients from corporate medicine.

But a bill that burdens emerging physician-led competitors while preserving much of the established healthcare system does not defeat corporate medicine.

It protects corporate medicine from competition.